StockData

Aytu BioPharma vs Zevra Therapeutics

AYTU and ZVRA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AYTU and ZVRA compare

Zevra Therapeutics is the larger company, worth 19 times as much as Aytu BioPharma ($558M against $28.9M).

Zevra Therapeutics grew revenue faster over the last twelve months (119% versus −13.3% for Aytu BioPharma).

Zevra Therapeutics keeps more of each dollar of sales as profit, with a net margin of 42.8% compared with −24.8% at Aytu BioPharma.

Zevra Therapeutics scores higher on the StockData Score (15 against 9 for Aytu BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAYTUZVRA
Size and price
Market cap$28.9M$558M
Share price$2.66$9.40
Change, 1 year27.3%5.9%
Change, 5 years−93.2%16.8%
Beta (5Y)−0.051.16
Employees7661
StockData Score
Total score915 (better)
Valuation score33
Growth score03 (better)
Performance score33
Health score36 (better)
Dividend score00
Valuation
P/E–10.1×
P/S0.5× (better)4.1×
P/B0.8× (better)2.6×
EV/EBITDA–4.0×
P/FCF8.9× (better)17.1×
FCF yield11.3% (better)5.8%
Fair value$8.97$23.57
Margin of safety70.4% (better)60.1%
Growth
Revenue growth (TTM)−13.3%119% (better)
Revenue growth, 5Y average−2.6%51.6% (better)
Net income growth (TTM)–2104%
Profitability
Gross margin64.0%95.5% (better)
Operating margin−14.4%60.5% (better)
Net margin−24.8%42.8% (better)
FCF margin5.6%24.0% (better)
Return on equity−52.6%34.8% (better)
Return on invested capital−63.5%–
Financial health
Debt / equity0.31 (better)0.00
Net debt / EBITDA–−2.64
Interest coverage−4.4×14.4× (better)
Current ratio1.135.17 (better)
Altman Z-score−4.024.35 (better)
Piotroski F-score36 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions45.3%78.5%
Held by insiders15.1%1.2%
Insider net buying, 12 months–−$2.5M
Short interest, % of float3.3%11.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.